* WuXi Biologics will provide an exclusive license to GSK for one preclinical bi-specific T cell ...
SHANGHAI, Dec. 15, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio", 2269.HK), a leading global Cont...
SHANGHAI, Oct. 27, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269. HK), a leading global Co...
- The 11th drug substance facility is released for cGMP operation in the WuXi Biologics' global ma...
* WuXi Biologics adds further capacity and capability for drug product fill & finish, providing g...
SHANGHAI, Oct. 13, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Co...
SHANGHAI, Oct. 11, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Con...
WUXI, China, Oct. 10, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio", 2269.HK), a leading global C...
WORCESTER, Mass., Sept. 29, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global Co...
WUXI, China, Sept. 20, 2022 /PRNewswire/ --WuXi Biologics ("WuXi Bio") (2269.HK), a leading global ...
CRANBURY, N.J., Aug. 31, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global leadi...
Revenue Increased by 63.5% Y-o-Y to RMB7,206.4 Million Gross Profit Increased by 48.6% Y-o-Y to RMB...
SHANGHAI, Aug. 16, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global leading Con...
* This investment will establish a cutting-edge, fully integrated CRDMO center inSingapore, inclu...
- The first GMP certificate that WuXi Vaccines has received from the regulatory agency - A critica...
SHANGHAI and SEOUL, South Korea, July 7, 2022 /PRNewswire/ -- WuXi XDC, a global leading CRDMO (Con...
* WuXi Biologics expands its extensive integrated CRDMO services by offering development and cGMP...
* WuXi Biologics offers global partners high-efficiency and high-quality manufacturing services f...
- WuXi Biologics has aligned its ESG strategy with the United Nations Sustainable Development Goa...
SINGAPORE, April 14, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global Contract ...